Adagio Medical Holdings (ADGM)
NASDAQ:ADGM
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.63 - $2.87
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$26.26M
Enterprise Value$36.17M
Total Cash (Recent Filing)$4.67M
Total Debt (Recent Filing)$21.97M
Price to Earnings (P/E)―
Beta-0.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,179,638
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.80
Price to Sales (P/S)59.32
P/FCF Ratio-0.51
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue-252.93
Enterprise Value/Gross Profit-33.87
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$4.00Price Target Upside270.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidencePublished Early Feasibility Study showing favorable safety and strong acute/chronic performance provides durable clinical validation for Adagio’s ULTC technology. Positive peer-reviewed data strengthens regulatory submissions, clinician adoption, and reimbursement discussions over the coming quarters, supporting commercialization prospects.
Board ExpertiseAdding a director with Medtronic experience enhances governance and commercial/operational guidance. Durable benefit: seasoned device executive can improve clinical trial design, regulatory strategy, and go-to-market planning, increasing likelihood of efficient product launches and stronger partnership negotiations.
Near-term Funding BoostA $19M private placement materially extends runway to support R&D and FDA submission activities. This funding reduces immediate solvency pressure, allowing focus on clinical development and regulatory milestones that are critical to achieving commercial revenue and de-risking the business over the next several months.
Bears Say
Negative Shareholders' EquityThe shift to negative shareholders’ equity materially weakens financial flexibility and increases insolvency risk. Negative equity constrains borrowing capacity, may tighten partner/contractor terms, and means future funding rounds or restructuring are likely required to sustain operations and execute commercialization plans.
Persistent Cash BurnConsistent negative operating and free cash flow indicate the company relies on external financing to operate. Persistent cash burn raises dilution and funding risk, limiting strategic flexibility and increasing the probability that additional capital raises or cost-cutting will be necessary before positive cash generation is achieved.
Minimal, Volatile Revenue & Deep LossesRevenue is minimal and volatile with TTM deterioration, while gross profit and operating profits remain deeply negative. This indicates the business is far from break-even and that commercial traction and margin sustainability are unproven, heightening execution risk as the company scales product sales.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.63 and its highest was $2.87 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $26.26M.
When is Adagio Medical Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Adagio Medical Holdings’s earnings last quarter?
Currently, no data Available
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 21,179,638 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$4.00
▲(270.37% Upside)
Technical Analysis
Co-Diagnostics
―
PAVmed
―
Vivos Therapeutics
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―